Amazon Prime Air Cargo Plane Crash Kills Five at Miami Airport 
RFK Jr. Orders Extended Hantavirus Quarantine for Cruise Passenger 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
AstraZeneca, Bristol Myers Squibb Explore Mega Merger Worth Nearly $400 Billion 
US-Backed Pediatric HIV Treatment Drops After Foreign Aid Changes, Study Finds 
Trump Signs Order to Cut Routine Childhood Vaccines 
Anthropic IPO Marketing Expected to Start in Mid-October 
The government is ‘doubling down’ on its social media ban. But bigger penalties for platforms aren’t enough 
New Mexico Measles Outbreak Cost Reached $5.4 Million, Study Finds 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
UNAIDS Urges U.S. to Reconsider South Africa HIV Funding Withdrawal 
France Keeps Top Health Alert as Officials Brace for Another Heatwave 
Nvidia CEO Says AGI Has Arrived With OpenAI GPT-6 Astra 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
GLP-1 Weight-Loss Drug Use Surges Among U.S. Children 
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss 
Add as a preferred source on Google
Shares of women’s healthcare company Organon & Co (NYSE: OGN) climbed sharply in after-hours trading on Thursday following reports that India-based Sun Pharmaceutical Industries Ltd. (NSE: SUN) is preparing a $13 billion acquisition offer. The news sparked strong investor interest, pushing Organon stock up as much as 8% to above $9.20 per share.
The surge comes despite Organon’s relatively modest market capitalization of $2.2 billion at the close of regular trading, highlighting the significant premium implied by the reported deal. According to sources cited by The Economic Times, Sun Pharma is planning to submit a binding all-cash offer, with financing reportedly backed by major global banks including JPMorgan, MUFG, and Citi.
The potential acquisition signals Sun Pharma’s strategic push to expand its footprint in the fast-growing women’s healthcare segment. Organon, a spin-off from Merck, specializes in reproductive health, biosimilars, and established medicines, making it an attractive target for global pharmaceutical companies seeking diversification and innovation in healthcare portfolios.
Reports also indicate that Sun Pharma intends to fully integrate Organon into its existing operations rather than issuing shares to Organon investors. This move suggests a long-term commitment to leveraging Organon’s capabilities, particularly its U.S.-based manufacturing infrastructure, which is considered a valuable asset in the pharmaceutical industry.
The deal has reportedly drawn competition from Germany’s Gruenthal, underscoring the increasing demand for companies focused on women’s health solutions. As pharmaceutical giants race to strengthen their pipelines and global reach, acquisitions like this could reshape the competitive landscape.
Investors and analysts are closely watching developments, as confirmation of the deal could significantly impact both companies’ valuations and the broader healthcare sector. The potential buyout highlights the growing importance of women’s health in global pharma strategies, while reinforcing Organon’s position as a key player in this specialized market.
